Acumen Pharmaceuticals Inc
ABOS
NGS
Sector: Professional, Scientific, and Technical Services
Industry: Research and Development in Biotechnology
4.88
USD
0.49
(11.16%)
Optionable: No Market Cap: 178 M 90-day average vol: 238,402
Previous close: 4.39 Open: 4.4 Bid: 4.94 Ask: 4.94
52 week range
3.02 26.98
Last updated: Thursday 30th June 2022
Chart
Financials
ABOS Income Statement
Annual
| Dec-19 | Dec-20 | Dec-21 | |
|---|---|---|---|
| Total revenues | 2 M | 0 | 0 |
| Cost of sales | 0 | 0 | -159000 |
| Gross operating profit | 2 M | 0 | 0 |
| Selling Gen & administrative expense | 926000 | -85000 | 7 M |
| Research & development expense | 9 M | 8 M | 12 M |
| Operating income | -8 M | -8 M | -20 M |
| floaterest income | 0 | 0 | 0 |
| floaterest expense | 0 | 0 | 0 |
| Other income net | -147000 | 586000 | -81 M |
| Pre-tax Income (EBT) | -8 M | -7 M | -101 M |
| Income taxes | 0 | 0 | 0 |
| Net income from total operations | -8 M | -7 M | -101 M |
| Minority floaterest | 0 | 0 | 0 |
| Total net income | -8 M | -7 M | -101 M |
| Preferred dividends | N/A | N/A | N/A |
| Net income available for common | -8 M | -7 M | -101 M |
| Depreciation | 0 | 0 | 159000 |
| Amortization | 0 | 0 | 0 |
| Operating income before depreciation (EBITDA) | -8 M | -8 M | -20 M |
| Total Income available for floaterest expense (EBIT) | 0 | 0 | 0 |
| Basic EPS total | -0.27 | -0.28 | -5.02 |
| Diluted EPS total | -0.27 | -0.28 | -5.02 |
Top MarketXLS Rank stocks
Stand with Ukraine
As the situation in Ukraine escalates, many of us in MarketXLS are left with emotions too overwhelming to name. If you’d like to show your support, but aren’t sure how to, we want to help make it easier for you to act.
For any amount donated, we’ll extend your MarketXLS subscription for double of the donated amount. Please send proof of your payment to support@marketxls.com to avail the extention
From all of us at MarketXLS, thank you!